The 2026 Telehealth Vertical Map: Where the Growth Actually Is
Most people evaluating a telehealth business are staring at one vertical: GLP-1 weight loss. That is like evaluating the internet in 1999 by looking only at bookstores. Here is the actual map, with the public numbers behind it.
GLP-1: proven, enormous, and crowded
Demand is not a theory. RAND published research finding that roughly one in eight American adults has already used a GLP-1 medication. The category built the modern telehealth industry, and every brand still needs it in the catalog, including brand-name pathways for the pens and pills patients ask for by name.
But the 2021 GLP playbook, a splash page and a low price, is dead. The ad auctions are among the most contested in consumer health, and a GLP-only brand is competing on price against everyone. GLP belongs in your catalog. It should not be your whole catalog.
Women's hormones: the opening of the decade
Here is a story most investors have not caught up to. In 2002, the Women's Health Initiative study linked hormone therapy to breast cancer. For over two decades, prescriptions collapsed, providers pulled back, and an entire generation of women went untreated through perimenopause and menopause.
That era is ending in public view. Researchers have spent years re-examining the 2002 findings, leading voices in menopause medicine now argue the risks were dramatically overstated, and in 2025 the FDA moved to remove the black-box warning from low-dose vaginal estrogen. Consumer search interest in womens hormone therapy has multiplied over the past year as the story spreads.
The market is responding fast. Midi Health, a womens-hormone-focused telehealth company, has publicly reported projections of roughly one billion dollars in revenue. And the demand proxy nobody expected: Primal Queen, a supplement brand selling freeze-dried beef organs positioned for perimenopause symptoms, runs on the order of two thousand simultaneous Meta ads (you can watch them live in the Facebook Ads Library) and its founders have publicly described it as a thirty-plus million dollar per year brand. If women are buying beef organs at that scale for hormone symptoms, consider what happens when actual prescription care is one lead form away.
This is effectively a new vertical, open since late last year, and the whitespace is real. A GrowPro build ships with a hormone catalog spanning more than fifty protocol SKUs, estradiol in every delivery form, progesterone, testosterone for women, with at-home labs built into the clinical flow.
Men's TRT: the proven playbook
The mens testosterone market is mature, publicly estimated north of two billion dollars a year in the US, and its funnels have been iterated for a decade. That maturity is an advantage: the patient journey is understood, the retention pattern is understood, and monitored TRT is exactly the kind of care a labs-first platform is built for.
Peptides: the 800-pound gorilla in the waiting room
The FDA's Pharmacy Compounding Advisory Committee has been reviewing peptides category by category, with names like BPC-157, TB-500, MOTS-C, KPV, DSIP, Epitalon, and Semax on its published agendas, and additional peptides including GHK-Cu, LL-37, and Dihexa queued for review into 2027. Outcomes and timelines belong to the FDA, not to anyone's marketing deck. But the strategic point stands: the brands that own compliant infrastructure before regulatory windows open are the ones positioned to serve that demand. GHK-Cu skincare is already live in the market today.
Sexual health, NAD+, and the longevity umbrella
ED treatment is a steady, high-value category with oral and injectable protocols. NAD+ and adjacent longevity products round out a catalog that lets one brand serve one patient across many needs, which is where recurring revenue actually compounds.
The takeaway
Do not pick a vertical. Pick infrastructure that carries all of them, then lead your marketing through the door that is open widest. Right now, that door is hormones, with GLP and peptides wired in behind it.